Ibuprofen guaiacol ester

Ibuprofen guaiacol ester (AF 2259; Metoxibutropate) is an orally active mutual prodrug of Ibuprofen (HY-78131) and Guaiacol (HY-N1380), designed to reduce the gastrointestinal (GI) side effects of ibuprofen. Ibuprofen guaiacol ester inhibits the synthesis of prostaglandin. Ibuprofen guaiacol ester inherits the antipyretic, analgesic and anti-inflammatory properties of Ibuprofen and Guaiacol, but reduces gastric damage. Ibuprofen guaiacol ester can be used to alleviate gastric erosion/ulcers induced by classic anti-inflammatory agent (such as Ibuprofen) [1][2].

Product Specifications

CAS Number

[66332-77-2]

Product Name Alternative

Methoxybutropate; AF 2259; Metoxibutropate

UNSPSC

12352005

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ibuprofen-guaiacol-ester.html

Purity

98.49

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(OC1=CC=CC=C1OC)C(C)C2=CC=C(CC(C)C)C=C2

Molecular Formula

C20H24O3

Molecular Weight

312.40

References & Citations

[1]Fossati A, et al. Effects of metoxibutropate, ibuprofen and guaiacol on the gastrointestinal system. Int J Tissue React. 1991;13 (1) :45-50.|[2]V. Cioli, et al. A toxicological and pharmacological study of ibuprofen guaiacol ester (AF 2259) in the rat. Toxicology and Applied Pharmacology. 1980, 54 (2) : 332-339.